Checkmate Pharmaceuticals Revenue and Competitors

Location

Total Funding

Industry

Estimated Revenue & Valuation

Checkmate Pharmaceuticals's estimated annual revenue is currently $2.3M per year.(i)
Checkmate Pharmaceuticals's estimated revenue per employee is $155,000

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 Ultivue	$12.7M	82	-45%	$107.3M	N/A
#2 Ohana Bioscienc...	$0.2M	1	-50%	N/A	N/A
#3 Matterworks	$6.2M	40	21%	N/A	N/A
#4 Tango Therapeut...	$42.2M	218	4%	$165M	N/A
#5 Gelesis	$14.6M	94	-37%	$312.8M	N/A
#6 BOSLab	$0.3M	2	-67%	N/A	N/A
#7 Akebia Therapeu...	$235M	366	-5%	$340.9M	N/A
#8 Elucidata Corpo...	$56M	289	-7%	$7.6M	N/A
#9 TRIANA Biomedic...	$4.7M	61	36%	N/A	N/A
#10 Gensaic	$2M	13	8%	N/A	N/A

Checkmate Pharmaceuticals is a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer.

keywords:N/A

N/A

Total Funding

Number of Employees

$2.3M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Global Strategic Fund I. Venbio Sells 27,668 Shares. Posted by admin on Apr 26th...

Regeneron will increase its research efforts in immuno-oncology through the all-cash acquisition of Checkmate Pharmaceuticals.

Regeneron plans to show there is more to skin cancer than PD-1 inhibitors through the $250 million acquisition of Checkmate Pharmaceuticals...

Company Name	Revenue	Number of Employees	Employee Growth	Total Funding
#1 10to8-Appointme...	$1.3M	15	N/A	N/A
#2 VirZOOM	$2.4M	15	-12%	N/A
#3 Centre for Comp...	$1.3M	15	-6%	N/A
#4 Ensemble Therap...	$2.3M	15	0%	N/A
#5 Piatrika Biosys...	$1.3M	15	-12%	N/A